In Section C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Members will get treatment until finally disorder progression or perhaps the members are not able to tolerate the study drugs. - "Our study discovered the very important purpose with the KLF16/MYC https://johnh554ugr7.jasperwiki.com/user